Use of a trans-amantadine derivative or its salt

Claims

1. The use of a trans-amantadine derivative having a structure represented by Formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicinal product for the prevention and / or treatment of lung injury:

2. The use according to paragraph 1, characterized in that it includes use in the manufacture of a medicinal product for the prevention and / or treatment of acute lung injury.

3. The use according to paragraph 1, characterized in that it includes use in the manufacture of a medicinal product for the prevention and / or treatment of acute respiratory distress syndrome caused by lung damage.

4. The use according to any one of paragraphs 1-3, characterized in that the pharmaceutically acceptable salt is formed by a derivative of trans-adamantane and an acid.

5. The use according to claim 1, wherein the pharmaceutically acceptable salt comprises acetate, hydrogen sulfate, ascorbate, benzoate, benzenesulfonate, citrate, fumarate, hydrochloride, hydrobromide, maleate, methanesulfonate, nitrate, oxalate, phosphate, succinate or sulfate.

6. The use according to paragraph 5, characterized in that the pharmaceutically acceptable salt is selected from: trans-4-[(2-amino-3,5-dibromobenzyl)amino]adamantan-1-ol hydrochloride, trans-4-[(2-amino-3,5-dibromobenzyl)amino]adamantan-1-ol hydrogen sulfate and trans-4-[(2-amino-3,5-dibromobenzyl)amino]adamantan-1-ol hydrobromide; preferably a hydrochloride having a structure represented by Formula V:

Images